Novo Nordisk’s Phase 3a PIONEER TEENS trial found that oral semaglutide significantly lowered blood sugar in adolescents with type 2 diabetes compared with placebo and was well tolerated. The company ...

Novo Nordisk reports phase III teen study success for oral semaglutide, showing strong HbA1c reduction and paving the way for the first oral GLP-1 for youth.

Novo Nordisk said Thursday it will seek federal approval to expand the use of its Ozempic and Rybelsus pills to kids and ...

Hollywood’s weight-loss drug conversation has officially moved from bodies to faces. The term “Ozempic face” is used for the ...

Telangana DCA cracks down on weight-loss drug violations, 75 medical shops face action: Our Bureau, Chennai Friday, April 24, 2026, 11:15 Hrs [IST] The Drugs Control Administratio ...

Novo Nordisk's oral GLP‑1 diabetes pill lowered blood sugar in children and teens with type 2 diabetes in a late-stage trial, potentially becoming the first approved oral GLP‑1 therapy for young ...

Novo Nordisk (CPSE:NOVO B) reported strong phase 3 trial results for its oral semaglutide in children and adolescents with type 2 diabetes. The company plans to file for US and EU label expansions to ...

Amazon is stepping into the weight loss drug scene, launching a program for GLP-1 medications like Rybelsus and Ozempic, ...

Novo Nordisk's oral GLP-1 drug significantly lowered blood sugar levels in children and adolescents with ​type 2 diabetes, ...

The PIONEER TEENS trial compared oral semaglutide at maximum tolerated doses with placebo in adolescents aged 10 to 17 years with T2D.

Novo Nordisk said April 23 it plans to seek expanded FDA approval for its Ozempic pill in the second half of 2026, which would make the drug the first oral GLP-1 approved for children and adolescents ...

Telangana, has issued show cause notices to 75 medical shops in Hyderabad for violations related to the sale of weight loss ...